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Study Objectives: Few studies have examined associations between sleep duration with 
combined and site-specific cancers within the same cohort. Additionally, no study to date has 
assessed associations between sleep timing midpoint and cancer incidence. Therefore, we aimed 
to investigate associations between self-reported sleep duration and sleep timing midpoint with 
combined and site-specific cancer incidence in Alberta’s Tomorrow Project (ATP) cohort. 
Methods: The sleep duration analysis included 45,984 Albertans aged 35–69 years recruited 
from 2001–2015. Sleep timing midpoint (wake-time − ½ sleep duration) was assessed in a subset 
of ATP participants (n = 19,822). Incident cancer cases were determined through linkage with 
the Alberta Cancer Registry in June 2017. Cox proportional hazard regression models evaluated 
the effects of sleep duration and sleep timing midpoint on combined and seven site-specific 
cancers. Results: A total of 2,428 and 1,322 incident cancer cases were observed in the sleep 
duration and sleep timing analyses, respectively. Reporting >9 h of sleep/night versus 7–9 h of 
sleep/night was associated with an increased incidence of non-Hodgkin lymphoma (hazard ratio 
[HR] = 2.14, 95% confidence interval [CI]: 1.14–4.01; p = 0.02) and hematological (HR = 1.70, 
95% CI: 1.03–2.82; p = 0.04) cancers. A later sleep timing midpoint (>4 h 8 min) versus an 
intermediate sleep timing midpoint (3 h 47 min–4 h 8 min) was associated with an increased 
incidence of combined (HR = 1.20, 95% CI: 1.04–1.37; p = 0.01) and breast (HR = 1.49, 95% 
CI: 1.09–2.03; p = 0.01) cancers. Conclusions: Sleep duration and sleep timing may play a role 
in cancer etiology. Studies including objective sleep assessments are needed to corroborate these 
findings. 
 




Statement of Significance 
There is an increasing prevalence of regular circadian misalignment and voluntary sleep 
restriction in industrialized societies. This is the largest study in Canada to date to examine 
associations between sleep duration with cancer incidence, and the first study to investigate 
associations between sleep timing midpoint with cancer incidence. Our study also assessed 
important effect modifiers in the sleep–cancer association (sex, body mass index, presence of 
medical conditions/comorbidities, alcohol intake, presence of depression, menopausal status), 
which suggest that other biological and behavioral components may directly impact this 
association. The findings from this study suggest that both sleep duration and sleep timing 
may impact cancer risk. Future studies including objective sleep assessments are needed to 




A Joint Consensus Statement from the American Academy of Sleep Medicine and the Sleep 
Research Society recommends that adults obtain at least 7 h of sleep/night for optimal health [1]. 
Furthermore, shorter (<7 h of sleep/night) and/or longer (>9 h of sleep/night) sleep durations 
have been consistently associated with a number of adverse health outcomes, such as obesity [2–
6], type 2 diabetes [7–9], the metabolic syndrome [10], cardiovascular disease [11, 12], and all-
cause mortality [13–16]. However, inconsistent results have been reported between sleep 
duration with combined and site-specific cancer risk [17–21]. More specifically, some studies 
reported U-shaped associations [22, 23], whereas others reported either positive [18, 24–26], 
inverse [27–34], or no [35–43] associations between sleep duration with combined and/or site-
specific cancer incidence. Meta-analyses [17, 19–21] also did not identify any statistically 
significant associations between short and long sleep durations with cancer risk. These 
inconsistencies in results may be partly explained by the different biologic pathways 
hypothesized to lead to the development of cancer at different sites [18, 19]. For instance, altered 
metabolism leading to obesity (e.g. increased orexigenic hormones and cortisol release, altered 
glucoregulatory responses/insulin resistance) [44–46] and/or lower melatonin levels [28, 47, 48] 
that occur in response to shorter sleep durations may increase sex hormone levels and the 
development of hormone-related cancers [19]. Conversely, positive associations between sleep 
duration and cancer risk may be related to the presence of other comorbidities/chronic health 
conditions and/or poorer sleep quality which may increase total time in bed and confound the 
sleep-cancer risk association [15, 26, 49, 50]. 
 
In addition to total sleep duration, sleep timing (bed- and wake-time) has been recently 
associated with adverse health outcomes [51–53]. Specifically, a later sleep timing midpoint 
(calculated as wake-time − ½ of total sleep duration) has been associated with a higher body 
mass index (BMI) [51], as well as an increased risk of insulin resistance [53] and gestational 
diabetes [52]. Studies assessing habitual chronotypes and cancer risk have also reported that 
individuals with an evening or mixed (i.e. neither morning nor evening) chronotype have an 
increased risk of developing breast [54, 55] or prostate [40, 56, 57] cancer compared with 
morning chronotypes. Erren et al. [17] have also suggested that sleep timing and chronotype may 
be indirectly associated with cancer risk based on evidence that being awake during our “internal 
biological night” leads to disruptions in the circadian rhythm, affecting behavioral and hormonal 
rhythms and clock gene expressions which may accelerate tumor development. No study to date 
has investigated the association between sleep timing midpoint and cancer risk. 
 
Alberta’s Tomorrow Project (ATP) is a prospective cohort study that collected information on 
lifestyle, behavioral and environmental exposures from 2001 to 2015 in Albertans (Canada) and 
aims to examine the impact of these exposures on the incidence of cancer and other chronic 
diseases [58]. The primary aim of this article was to investigate the strength of the associations 
between baseline sleep duration with combined and site-specific cancer incidence among 
participants of ATP. Our secondary aim was to assess the strength of associations between sleep 





Setting and participants 
 
The study flow chart for these analyses is presented in Figure 1. A total of 55,530 Albertans aged 
35–69 years were enrolled into a prospective cohort study between 2001 and 2015. Full details 
pertaining to participant recruitment, enrollment, and data collection methods for Phase I of ATP 
(participants enrolled between 2001 and 2008) have been described elsewhere [58]. Interested 
participants were mailed an information package and were considered enrolled in the study if 
they completed and returned the Health and Lifestyle Questionnaire and signed the consent form. 
Participants who were pregnant at the time of enrollment, did not consent to data linkage with 
the Alberta Cancer Registry (ACR) or had a personal history of cancer other than nonmelanoma 
skin cancer (n = 1,326) were subsequently removed from the dataset. Ethical approval was 




Figure 1. Study flow chart for the sleep duration (A) and sleep timing midpoint (B) analyses, 
Alberta’s Tomorrow Project, 2001–2015.  




Sleep duration was first self-reported by participants who completed Survey 2004 (participants 
enrolled from 2001 to 2003) with the following question: “On average, how many hours did you 
sleep each night during the past 4 weeks?” Participants who completed Survey 2008 (participants 
enrolled from 2001 to 2007) reported habitual bed- and wake-times with the following questions: 
“On average over the past 7 days, at what time did you normally go to sleep?” and “On average 
over the past 7 days, at what time did you normally wake up?” This information was used to 
derive habitual sleep duration for these participants. Sleep duration was also assessed with the 
Updated Health and Lifestyle Questionnaire and the CORE Questionnaire in Albertans enrolled 
from 2008 to 2015 as part of the Canadian Partnership for Tomorrow Project (CPTP) with the 
following question: “On average, how many hours per day do you usually sleep, including naps? 
A day refers to a 24-hour period.” Baseline sleep duration (n = 46,331) was identified as the first 
time each participant completed one of the abovementioned questionnaires. 
 
Bed- and wake-times were assessed in participants who completed Survey 2008 (n = 20,265). 
Sleep timing midpoint (wake-time − ½ of total sleep duration) was calculated for each 
participant since this variable has been shown to be a valid marker of sleep chronotype [59]. 
 
Cancer incidence rates 
 
Primary cancers were identified through data linkage with the ACR using participants’ personal 
health numbers in June 2017. The ACR is a population-based registry and it is mandatory for 
physicians and laboratories throughout Alberta to report all cancer cases to the ACR. 
 
Site-specific cancers were included in the present analyses if >100 incident cases were noted in 
the cohort with sleep duration or sleep timing midpoint as the exposure of interest. In the sleep 
duration analysis, seven cancer sites were included: breast, colon (includes cancers of the colon 
and rectosigmoid junction), prostate, lung, endometrial, non-Hodgkin lymphoma, and 
hematological cancers (includes Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, 
multiple myeloma and plasmacytoma, and other hematopoeitic and reticuloendothelioma 
cancers). In the sleep timing midpoint analysis, five cancer sites were included: breast, 
colorectal, lung, prostate, and hematological cancers. Given that our analytical plan developed a 
priori was to examine sleep duration and sleep timing midpoint by categories, we selected 100 
cases for inclusion in the site-specific analyses as a general threshold for reasonable statistical 
power to avoid reporting overly wide confidence intervals and potentially spurious associations. 
This approach also allowed for some degree of exploratory analyses in less common cancer sites 




Covariates in the present paper were selected based on scientific plausibility and associations 
between the exposure (sleep) and cancer incidence [3, 5, 7, 11, 60–65]. The cutoff points used 
for these covariates are based on scientific plausibility/cutoff points used in the literature and/or 
the distribution of responses in this cohort. These included: age (years), sex (male/female), 
marital status (married or living with someone/divorced, separated, or widowed/single, never 
married), total household income ($0–$49,999/$50,000–$99,999/≥$100,000), highest level of 
education (high school or less/some posthigh school education or a posthigh school certificate or 
degree), employment status (yes/no), ethnicity (Caucasian/Other), smoking status 
(daily/occasional/former/never), alcohol intake (daily/weekly/monthly/never), BMI (<25 
kg/m2/≥25 kg/m2), presence of at least one medical condition/comorbidity, such as 
cardiovascular disease, respiratory disease, diabetes (yes/no), presence of depression (yes/no), 
and having a family history of cancer (yes/no). For cancer sites that only included female cases 
(breast and endometrial cancers), menopausal status (premenopausal/postmenopausal) and 
gravidity (≤3 full-term pregnancies/>3 full-term pregnancies) were included in the adjusted 
models. Sleep duration (hours) was added as a covariate in models with sleep timing midpoint as 
the predictor. Data on these covariates for each participant were selected from their baseline 
questionnaire (i.e. the questionnaire reporting data on the sleep variable of interest) to avoid 
potential mediation of variables that may change over time, such as BMI, smoking status, and 
alcohol intake. Participants with missing data for any of these covariates were assigned a 
categorical value that was associated with “missing data” for each covariate (e.g. 0—BMI <25 
kg/m2, 1—BMI ≥25 kg/m2, 2—missing value for BMI; 0—never, 1—monthly, 2—weekly, 3—
daily, 4—missing value for alcohol intake). This approach was taken to avoid removal of 
participants with missing covariate data from the multivariate-adjusted models without 




The follow-up time for each participant was calculated from the date of questionnaire completion 
which contained their baseline sleep variable to their date of cancer diagnosis or to the end of 
follow-up for the present analyses. To do so, the elapsed “calendar time” (365.2425 d/year) 
between their exact age at questionnaire completion and their exact age at cancer diagnosis or 
end of follow-up was estimated. In this instance, exact age refers to the elapsed “calendar time” 
(365.2425 d/year) between date of birth and questionnaire completion, as well as cancer 
diagnosis or end of follow-up. Therefore, each participant contributed person-time from the 
completion of their baseline sleep questionnaire to their diagnosis of cancer or to the end of 




All analyses were performed using STATA v14 (College Station, TX). Descriptive data are 
presented as means ± standard deviations for continuous variables and as counts and percentages 
for categorical variables. Differences in descriptive data between cancer cases and noncancer 
cases were assessed using an analysis of variance test for continuous variables and a chi-square 
test for categorical variables. Sleep duration was modeled as a categorical variable because of the 
potential U-shaped associations between sleep duration and chronic disease/all-cause mortality 
[6, 7, 9, 11–16]. The groupings used to define sleep duration were as follows: <7 h of sleep/night 
(short sleep duration), 7–9 h of sleep/night (recommended sleep duration), and >9 h of 
sleep/night (long sleep duration). Since no recommendations currently exist for sleep timing 
midpoint and the association between sleep timing midpoint and cancer incidence is unknown, 
we created tertiles to compare an intermediate sleep timing midpoint (referent group) within this 
sample to an earlier and later sleep timing midpoint. Cutoff points to define earlier and later 
sleep timing midpoints have been used in previous studies [51, 52]. The cutoff points used to 
define tertiles in our sample are comparable to those used in the aforementioned studies [51, 52] 
and a population-based sample that identified 4 h 00 min as the 50th percentile for sleep timing 
midpoint [66]. 
 
Cox proportional hazards regression models were conducted to estimate multivariate-adjusted 
hazards ratios (HR) and 95% confidence intervals (95% CIs) between sleep duration (7–9 h of 
sleep/night as the referent group) or sleep timing midpoint (intermediate sleep timing midpoint 
as the referent group) groups with combined and site-specific cancer incidence. We formally 
tested the proportional hazards assumption for the combined and site-specific cancer incidence 
models and found no evidence of statistically significant differences (p < 0.05) in hazard across 
the follow-up period between sleep duration and sleep timing midpoint categories (results not 
shown). To address the potential issue of reverse causality (i.e. sleep could be influenced by 
physiological changes incurred as a result of an existing but undiagnosed cancer), we repeated 
the risk analyses after excluding cancer cases that were diagnosed <2 years (730.5 days) after 
baseline sleep data collection. 
 
Lastly, we examined potential effect modification for the association between sleep duration and 
sleep timing midpoint with combined cancer incidence in the multivariate-adjusted models by 
the following covariates: sex (male/female), BMI (<25 kg/m2/≥25 kg/m2), presence of medical 
conditions/comorbidities (yes/no), and presence of depression (yes/no). Effect modification for 
the association between sleep duration with alcohol intake (daily/weekly/monthly/never) and 
menopausal status (premenopausal/postmenopausal) were also tested. Statistical significance was 




Participant characteristics, according to sex and case status, for 45,984 participants (16,557 
males and 29,427 females) included in the sleep duration analysis are presented in Table 1. Of 
these, a total of 2,428 participants (1,038 males and 1,390 females) were diagnosed with cancer 
during the study follow-up period. The mean follow-up times for cancer and noncancer cases 
were 4.78 ± 3.20 and 7.47 ± 3.25 years, respectively, yielding a total of 336,892 person-years of 
follow-up. Cancer cases were older, had longer sleep durations and a higher BMI compared to 
noncancer cases. A larger proportion of cancer cases were also Caucasian, less educated, had a 
lower total household income, were unemployed, were daily smokers, had at least one medical 
condition/comorbidity, had a family history of cancer and were postmenopausal (females only) 
compared with noncancer cases. 
 
Table 1. Descriptive statistics for Alberta’s Tomorrow Project study participants who provided data on sleep duration and consented 
to data linkage, n = 45,984, 2001–2015 
 Mean (standard deviation and/or standard error of the mean*) or N (%)  






cases All cancer cases All noncancer cases P-value† 
 (n = 1038) (n = 15,519) (n = 1,390) (n = 28,037) (n = 2,428) (n = 43,556)  
Follow-up time (years)  4.81 (3.26) 7.68 (3.28) 4.76 (3.16) 7.35 (3.22) 4.78 (3.20) 7.47 (3.25) <0.0001 
Sleep duration (h:min)  7 h 29 min  
(1 h 13 min) 
7 h 22 min  
(1 h 5 min) 
7 h 33 min  
(1 h 20 min) 
7 h 31 min  
(1 h 11 min) 
7 h 31 min  
(1 h 17 min) 
7 h 27 min  
(1 h 9 min) 
0.01 
Sleep duration category  
       
 Recommended sleep duration  754 (72.6%) 11,120 (71.7%) 972 (69.9%) 20,665 (73.7%) 1,726 (71.1%) 31,785 (73.0%) 0.61 
 Short sleep duration  229 (22.1%) 3,782 (24.4%) 302 (21.7%) 5,721 (20.4%) 531 (21.9%) 9,503 (21.8%) 1.00 
 Long sleep duration  55 (5.3%) 617 (4.0%) 116 (8.4%) 1,651 (5.9%) 171 (7.0%) 2,268 (5.2%) 0.001 
Age (years)*  60.0 (7.7, 0.24) 53.8 (9.3, 0.07) 58.0 (8.8, 0.24) 52.8 (9.2, 0.05) 58.9 (8.4, 0.17) 53.2 (9.3, 0.04) <0.0001 
Body mass index (kg/m2)*  28.7 (4.6, 0.15) 27.9 (4.4, 0.04) 28.2 (6.3, 0.19) 27.0 (5.8, 0.04) 28.4 (5.6, 0.12) 27.4 (5.3, 0.03) <0.0001 
Body mass index category  
       
 Body mass index <25 kg/m2  165 (15.9%) 3,030 (19.5%) 397 (28.6%) 8,994 (32.1%) 562 (23.2%) 12,024 (27.6%) 0.0002 
 Body mass index ≥25 kg/m2  745 (71.8%) 9,266 (59.7%) 757 (54.5%) 11,920 (42.5%) 1,502 (61.9%) 21,186 (48.6%) <0.0001 
 Missing  128 (12.3%) 3,223 (20.8%) 236 (17.0%) 7,123 (25.4%) 364 (15.0%) 10,346 (23.8%) <0.0001 
Ethnicity  
       
 Caucasian  911 (87.8%) 12,568 (81.0%) 1,176 (84.6%) 22,562 (80.5%) 2,087 (86.0%) 35,130 (80.7%) 0.02 
 Other  61 (5.9%) 1,509 (9.7%) 96 (6.9%) 2,420 (8.6%) 157 (6.5%) 3,929 (9.0%) 0.0002 
 Missing  66 (6.4%) 1,442 (9.3%) 118 (8.5%) 3,055 (10.9%) 184 (7.6%) 4,497 (10.3%) 0.0002 
Marital status  
       
 Married or living with someone  865 (83.3%) 12,975 (83.6%) 991 (71.3%) 21,085 (75.2%) 1,856 (76.4%) 34,060 (78.2%) 0.64 
 Divorced, separated or widowed  125 (12.0%) 1,530 (9.9%) 317 (22.8%) 5,119 (18.3%) 442 (18.2%) 6,649 (15.3%) 0.002 
 Single, never married  48 (4.6%) 1,009 (6.5%) 82 (5.9%) 1,824 (6.5%) 130 (5.4%) 2,833 (6.5%) 0.10 
Missing  0 (0%) 5 (0.1%) 0 (0%) 9 (0.1%) 0 (0%) 14 (0.03%) 0.67 
Education  
       
 High school or less  264 (25.4%) 2,834 (18.3%) 382 (27.5%) 6,103 (21.8%) 646 (26.6%) 8,937 (20.5%) <0.0001 
 Some post-high school education or 
a post-high school degree or certificate  
691 (66.6%) 12,093 (77.9%) 890 (64.0%) 21,104 (75.3%) 1,581 (65.1%) 33,197 (76.2%) <0.0001 
 Missing  83 (8.0%) 592 (3.8%) 118 (8.5%) 830 (3.0%) 201 (8.3%) 1,422 (3.3%) <0.0001 
Total household income  
       
 $0–$49,999  208 (20.0%) 1,923 (12.4%) 372 (26.8%) 5,260 (18.8%) 580 (23.9%) 7,183 (16.5%) <0.0001 
 $50,000–$99,999  360 (34.7%) 4,655 (30.0%) 450 (32.4%) 8,437 (30.1%) 810 (33.4%) 13,092 (30.1%) 0.02 
 ≥$100,000  341 (32.9%) 7,734 (49.8%) 362 (26.0%) 11,721 (41.8%) 703 (29.0%) 19,455 (44.7%) <0.0001 
 Missing  129 (12.4%) 1,207 (7.8%) 206 (14.8%) 2,619 (9.3%) 335 (13.8%) 3,826 (8.8%) <0.0001 
 Mean (standard deviation and/or standard error of the mean*) or N (%)  






cases All cancer cases All noncancer cases P-value† 
 (n = 1038) (n = 15,519) (n = 1,390) (n = 28,037) (n = 2,428) (n = 43,556)  
Employment status  
       
 Yes  652 (62.8%) 12,085 (77.9%) 728 (52.4%) 18,660 (66.6%) 1,380 (56.8%) 30,745 (70.6%) <0.0001 
 No  386 (37.2%) 3,417 (22.0%) 662 (47.6%) 9,355 (33.4%) 1,048 (43.2%) 12,772 (29.3%) <0.0001 
 Missing  0 (0%) 17 (0.1%) 0 (0%) 22 (0.1%) 0 (0%) 39 (0.1%) 0.33 
Alcohol intake  
       
 Never  132 (12.7%) 1,609 (10.4%) 201 (14.5%) 3,123 (11.1%) 333 (13.7%) 4,732 (10.9%) 0.0002 
 Monthly  243 (23.4%) 4,093 (26.4%) 537 (38.6%) 11,205 (40.0%) 780 (32.1%) 15,298 (35.1%) 0.05 
 Weekly  423 (40.8%) 6,695 (43.1%) 360 (25.9%) 9,541 (34.0%) 783 (32.3%) 16,236 (37.3%) 0.0004 
 Daily  121 (11.7) 1,521 (9.8%) 96 (6.9%) 1,618 (5.8%) 217 (8.9%) 3,139 (7.2%) 0.01 
 Missing  119 (11.5%) 1,601 (10.3%) 196 (14.1%) 2,550 (9.1%) 315 (13.0%) 4,151 (9.5%) <0.0001 
Smoking status  
       
 Never  563 (54.2%) 8,875 (57.2%) 760 (54.7%) 16,631 (59.3%) 1,323 (54.5%) 25,506 (58.6%) 0.04 
 Former  318 (30.6%) 4,842 (31.2%) 385 (27.7%) 8,631 (30.8%) 703 (29.0%) 13,473 (30.9%) 0.23 
 Occasional  26 (2.5%) 438 (2.8%) 25 (1.8%) 560 (2.0%) 51 (2.1%) 998 (2.3%) 0.82 
 Daily  131 (12.6%) 1,333 (8.6%) 220 (15.8%) 2,175 (7.8%) 351 (14.5%) 3,508 (8.1%) <0.0001 
 Missing  0 (0%) 31 (0.2%) 0 (0%) 40 (0.1%) 0 (0%) 71 (0.2%) 0.14 
Presence of at least one medical condition or comorbidity  
     
 No  293 (28.2%) 6,315 (40.7%) 327 (23.5) 9,476 (33.8%) 620 (25.5%) 15,791 (36.3%) <0.0001 
 Yes  741 (71.4%) 9,127 (58.8%) 1,060 (76.3%) 18,487 (65.9%) 1,801 (74.2%) 27,614 (63.4%) <0.0001 
 Missing  4 (0.4%) 77 (0.5%) 3 (0.2%) 74 (0.3%) 7 (0.3%) 151 (0.4%) 0.90 
Presence of depression  
       
 No  470 (45.3%) 9,081 (58.5%) 595 (42.8%) 15,747 (56.2%) 1,065 (43.9%) 24,828 (57.0%) <0.0001 
 Yes  138 (13.3%) 1,924 (12.4%) 291 (20.9%) 5,234 (18.7%) 429 (17.7%) 7,158 (16.4%) 0.35 
 Missing  430 (41.4%) 4,514 (29.1%) 504 (36.3%) 7,056 (25.2%) 934 (38.5%) 11,570 (26.6%) <0.0001 
Menopausal status  
       
 Premenopausal  NA NA 304 (21.9%) 10,990 (39.2%) 
  
<0.0001 
 Postmenopausal  NA NA 879 (63.2%) 14,317 (51.1%) 
  
<0.0001 
 Missing  NA NA 207 (14.9%) 2,730 (9.7%) 
  
<0.0001 
Gravidity  NA NA 2.5 (1.2, 0.03) 2.3 (1.2, 0.01) 
  
<0.0001 
Gravidity category  
       
 ≤3 full-term pregnancies  NA NA 1,015 (73.0%) 21,476 (76.6%) 
  
0.33 
 >3 full-term pregnancies  NA NA 219 (15.8%) 2,777 (9.9%) 
  
<0.0001 
 Missing  NA NA 156 (11.2%) 3,784 (13.5%) 
  
0.08 
Family history of cancer  
       
 Mean (standard deviation and/or standard error of the mean*) or N (%)  






cases All cancer cases All noncancer cases P-value† 
 (n = 1038) (n = 15,519) (n = 1,390) (n = 28,037) (n = 2,428) (n = 43,556)  
 No  589 (56.7%) 11,433 (73.7%) 789 (56.8%) 20,753 (74.0%) 1,378 (56.8%) 32,186 (73.9%) <0.0001 
 Yes  449 (43.3%) 4,086 (26.3%) 601 (43.2%) 7,284 (26.0%) 1,050 (43.3%) 11,370 (26.1%) <0.0001 
NA, not applicable. 
*The standard deviation and standard error of the mean are presented for continuous age and body mass index variables. 
†p-Values for the differences in descriptive data between all cancer cases and all noncancer cases. Bold values indicate statistically significant differences in 
descriptive data between cancer and noncancer cases, which is set at p <0.05. 
 
Table 2. Descriptive statistics for Alberta’s Tomorrow Project study participants who have data on sleep timing midpoint and 
consented to data linkage, n = 19,822, 2001–2015 
 Mean (standard deviation and/or standard error of the mean*) or N (%)  
 Male cancer cases 
Male noncancer 
cases Female cancer cases 
Females noncancer 
cases All cancer cases All noncancer cases P-value† 
 (n = 585) (n = 6,933) (n = 737) (n = 11,567) (n = 1,322) (n = 18,500)  
Follow-up time (years)  4.56 (2.49) 8.71 (0.23) 4.41 (2.45) 8.70 (0.22) 4.48 (2.46) 8.70 (0.22) <0.0001 
Sleep timing midpoint (clock time)  3:59 am (33 min) 3:53 am (32 min) 4:04 am (34 min) 4:02 am (32 min) 4:02 am (34 min) 3:58 am (32 min) 0.05 
Sleep timing midpoint category  
       
 Intermediate sleep timing midpoint  198 (33.9%) 2,389 (34.5%) 207 (28.1%) 4,044 (35.0%) 405 (30.6%) 6,433 (34.8%) 0.05 
 Early sleep timing midpoint  193 (33.0%) 2,811 (40.6%) 207 (28.1%) 3,136 (27.1%) 400 (30.3%) 5,947 (32.2%) 0.50 
 Late sleep timing midpoint  194 (33.2%) 1,733 (25.0%) 323 (43.8%) 4,387 (37.9%) 517 (39.1%) 6,120 (33.1%) 0.001 
Sleep duration (h:min)  7 h 46 min 
(1 h 12 min) 
7 h 35 min 
(1 h 5 min) 
7 h 50 min 
(1 h 18 min) 
7 h 52 min 
(1 h 8 min) 
7 h 48 min 
(1 h 16 min) 
7 h 46 min 
(1 h 8 min) 
0.20 
Age (years)*  61.1 (8.1, 0.33) 55.0 (8.9, 0.11) 60.3 (8.8, 0.32) 55.0 (9.1, 0.08) 60.7 (8.5, 0.23) 55.0 (9.0, 0.07) <0.0001 
Body mass index (kg/m2)*  28.8 (4.8, 0.20) 28.1 (4.4, 0.05) 28.2 (6.1, 0.23) 27.3 (5.8, 0.05) 28.5 (5.6, 0.16) 27.6 (5.4, 0.04) <0.0001 
Body mass index category  
       
 Body mass index <25 kg/m2  112 (19.2%) 1,543 (22.3%) 235 (31.9%) 4,593 (39.7%) 347 (26.3%) 6,136 (33.2%) 0.0001 
 Body mass index ≥25kg/m2  467 (79.8%) 5,320 (76.7%) 487 (66.1%) 6,760 (58.4%) 954 (72.2%) 12,080 (65.3%) 0.01 
 Missing  6 (1.0%) 70 (1.0%) 15 (2.0%) 214 (1.9%) 21 (1.6%) 284 (1.5%) 1.00 
Ethnicity  
       
 Caucasian  550 (94.0%) 6,333 (91.4%) 689 (93.5%) 10,638 (92.0%) 1,239 (93.7%) 16,971 (91.7%) 0.78 
 Other  34 (5.8%) 565 (8.2%) 44 (6.0%) 877 (7.6%) 78 (5.9%) 1,442 (7.8%) 0.06 
 Missing  1 (0.2%) 35 (0.5%) 4 (0.5%) 52 (0.5%) 5 (0.4%) 87 (0.5%) 0.90 
Marital status  
       
 Married or living with someone  493 (84.3%) 5,825 (84.0%) 528 (71.6%) 8,793 (76.0%) 1,021 (77.2%) 14,618 (79.0%) 0.78 
 Divorced, separated or widowed  64 (10.9%) 695 (10.0%) 173 (23.5%) 2,220 (19.2%) 237 (17.9%) 2,915 (15.8%) 0.16 
 Single, never married  28 (4.8%) 405 (5.8%) 36 (4.9%) 540 (4.7%) 64 (4.8%) 945 (5.1%) 0.90 
 Missing  0 (0%) 8 (0.1%) 0 (0%) 14 (0.1%) 0 (0%) 22 (0.1%) 0.45 
Education  
       
 Mean (standard deviation and/or standard error of the mean*) or N (%)  
 Male cancer cases 
Male noncancer 
cases Female cancer cases 
Females noncancer 
cases All cancer cases All noncancer cases P-value† 
 (n = 585) (n = 6,933) (n = 737) (n = 11,567) (n = 1,322) (n = 18,500)  
 High school or less  183 (31.3%) 1,593 (23.0%) 244 (33.1%) 3,136 (27.1%) 427 (32.3%) 4,729 (25.6%) <0.0001 
 Some post-high school education or a 
post-high school degree or certificate  
401 (68.6%) 5,330 (76.9%) 493 (66.9%) 8,420 (72.8%) 894 (67.6%) 13,750 (74.3%) 0.02 
 Missing  1 (0.2%) 10 (0.1%) 0 (0%) 11 (0.1%) 1 (0.1%) 21 (0.1%) 0.90 
Total household income  
       
 $0–$49,999  130 (22.2%) 1,051 (15.2%) 224 (30.4%) 2,814 (24.3%) 354 (26.8%) 3,865 (20.9%) <0.0001 
 $50,000–$99,999  219 (37.4%) 2,273 (32.8%) 261 (35.4%) 3,565 (30.8%) 480 (36.3%) 5,838 (31.6%) 0.01 
 ≥$100,000  192 (32.8%) 3,226 (46.5%) 163 (22.1%) 4,046 (35.0%) 355 (26.9%) 7,272 (39.3%) <0.0001 
 Missing  44 (7.5%) 386 (5.5%) 89 (12.1%) 1,142 (9.9%) 133 (10.1%) 4,387 (37.9%) 0.09 
Employment status  
       
 Yes  354 (60.5%) 5,362 (77.3%) 352 (47.8%) 7,179 (62.1%) 706 (53.4%) 12,541 (67.8%) <0.0001 
 No  231 (39.5%) 1,562 (22.5%) 385 (52.2%) 4,374 (37.8%) 616 (46.6%) 5,936 (32.1%) <0.0001 
 Missing  0 (0%) 9 (0.1%) 0 (0%) 14 (0.1%) 0 (0%) 23 (0.1%) 0.45 
Smoking status  
       
 Never  220 (37.6%) 3,277 (47.3%) 315 (42.7%) 6,009 (52.0%) 535 (40.5%) 9,286 (50.2%) <0.0001 
 Former  274 (46.8%) 2,675 (38.6%) 285 (38.7%) 4,115 (35.6%) 559 (42.3%) 6,790 (36.7%) 0.01 
 Occasional  8 (1.4%) 182 (2.6%) 17 (2.3%) 222 (1.9%) 25 (1.9%) 404 (2.2%) 0.78 
 Daily  80 (13.7%) 790 (11.4%) 118 (16.0%) 1,196 (10.3%) 198 (15.0%) 1,986 (10.7%) <0.0001 
 Missing  3 (0.5%) 9 (0.1%) 2 (0.3%) 25 (0.2%) 5 (0.4%) 34 (0.2%) 0.30 
Presence of at least one medical condition or comorbidity  
     
 No  99 (16.9%) 2,031 (29.3%) 132 (17.9) 2,990 (25.9%) 231 (17.5%) 5,021 (27.1%) <0.0001 
 Yes  483 (82.6%) 4,890 (70.5%) 603 (81.8%) 8,565 (74.1%) 1,086 (82.2%) 13,455 (72.7%) 0.001 
 Missing  3 (0.5%) 12 (0.2%) 2 (0.3%) 12 (0.1%) 5 (0.4%) 24 (0.1%) 0.07 
Presence of depression  
       
 No  456 (78.0%) 5,311 (76.6%) 536 (72.7%) 8,234 (71.2%) 992 (75.0%) 13,545 (73.2%) 0.74 
 Yes  129 (22.1%) 1,610 (23.2%) 199 (27.0%) 3,311 (28.6%) 328 (24.8%) 4,921 (26.6%) 0.47 
 Missing  0 (0%) 12 (0.2%) 2 (0.2%) 22 (0.2%) 2 (0.2%) 34 (0.2%) 0.95 
Gravidity  NA NA 2.6 (1.2, 0.05) 2.5 (1.2, 0.01) 
  
0.002 
Gravidity category  
       
 ≤3 full-term pregnancies  NA NA 536 (72.7%) 8,799 (76.1%) 
  
<0.0001 
 >3 full-term pregnancies  NA NA 130 (17.6%) 1,541 (13.3%) 
  
<0.0001 
 Missing  NA NA 71 (9.6%) 1,227 (10.6%) 
  
0.64 
Family history of cancer  
       
 No  248 (42.4%) 3,417 (49.3%) 282 (38.3%) 5,194 (44.9%) 530 (40.1%) 8,611 (46.6%) 0.004 
 Yes  337 (57.6%) 3,516 (50.7%) 455 (61.7%) 6,373 (55.1%) 792 (59.9%) 9,889 (53.5%) 0.01 
NA, not applicable. 
*The standard deviation and standard error of the mean are presented for continuous age and body mass index variables. 
†p-Values for the differences in descriptive data between all cancer cases and all noncancer cases. 
A U-shaped association between sleep duration, modeled as a continuous variable and adjusted 
for covariates, and combined cancer risk was observed (Figure 2). However, when presented as a 
categorical variable, short and long sleep durations were not significantly associated with 
combined cancer risk in the multivariate- and latency multivariate-adjusted models (Figure 3). 
For site-specific cancer incidence, long sleep duration was associated with an increased risk of 
non-Hodgkin lymphoma and hematological cancers in the multivariate- and latency multivariate-
adjusted models (Figure 3). 
 
 
Figure 2. Effects of sleep duration modeled as a continuous variable on combined cancer risk for 
45,984 participants in Alberta’s Tomorrow Project.  
Note: The model was adjusted for age, sex, total household income, employment status, marital status, education, 
ethnicity, alcohol intake, smoking status, body mass index, presence of at least one medical conditions/comorbidity, 
presence of depression, family history of cancer. 
 
The sleep duration × medical condition (p = 0.002) and sleep duration × menopausal status (p = 
0.001) interaction terms were associated with combined cancer incidence when added to the 
multivariate-adjusted model. However, sleep duration × sex (p = 0.30), sleep duration × BMI 
(p = 0.23), sleep duration × depression (p = 0.68) and sleep duration × alcohol intake (P = 0.17) 
interaction terms were not associated with combined cancer incidence in the multivariate-
adjusted model. When testing for effect modification, short sleep duration was associated with an 
increased risk of combined cancer incidence in females, but not males, as well as 
postmenopausal but not premenopausal females (Figure 4). Similarly, short sleep duration was 
associated with an increased risk of combined cancer incidence in daily alcohol drinkers, which 
was not present in participants who reported weekly, monthly, or no alcohol intake, as well as 
participants who reported having depression versus those who reported no depression (Figure 4). 
Lastly, both short and long sleep durations were associated with an increased risk of combined 
cancer incidence in participants who reported at least one medical condition/comorbidity, but not 




Figure 3. Cox regression hazard ratios of combined and site-specific cancer incidence and sleep 
duration groups for 45,984 participants in Alberta’s Tomorrow Project.  
Note: Recommended sleep duration (Ref) = 7–9 h/night, short sleep duration < 7 h/night, long sleep duration > 9 
h/night. The multivariate-adjusted models included the following covariates: age, sex (nonsex-specific cancers), 
total household income, employment status, marital status, education, ethnicity, alcohol intake, smoking status, body 
mass index, presence of at least one medical conditions/comorbidity, presence of depression, family history of 
cancer, menopausal status, and gravidity (breast and endometrial cancers only). The latency multivariate-adjusted 
models removed cancer cases diagnosed <2 years after questionnaire completion. **p < 0.01, *p < 0.05. HR, hazard 
ratio; CI, confidence interval. 
 
 
Figure 4. Cox regression hazard ratios of combined cancer incidence and sleep duration groups, 
stratified by sex, body mass index, alcohol intake, presence of at least one medical 
condition/comorbidity, presence of depression or menopausal status (females only) for 45,984 
participants in Alberta’s Tomorrow Project.  
Note: Recommended sleep duration (Ref) = 7–9 h/night, short sleep duration < 7 h/night, long sleep duration > 9 
h/night. The model was adjusted for age, sex (if not stratified variable and menopausal status as effect modifier), 
total household income, employment status, marital status, education, ethnicity, alcohol intake (if not stratified 
variable), smoking status, body mass index (if not stratified variable), presence of at least one medical 
conditions/comorbidity (if not stratified variable), presence of depression (if not stratified variable), family history 




Figure 5. Cox regression hazard ratios of combined and site-specific cancer incidence and sleep 
timing midpoint tertiles for 19,822 participants in Alberta’s Tomorrow Project.  
Note: Intermediate sleep timing midpoint (Ref) = 3 h 47 min–4 h 8 min, early sleep timing midpoint < 3 h 47 min, 
late sleep timing midpoint > 4 h 8 min. The multivariate-adjusted models included the following covariates: age, sex 
(nonsex-specific cancers), total household income, employment status, marital status, education, ethnicity, smoking 
status, body mass index, presence of at least one medical conditions/comorbidity, presence of depression, family 
history of cancer, sleep duration, and gravidity (breast cancer only). The latency multivariate-adjusted models 
removed cancer cases diagnosed <2 years after questionnaire completion. **p < 0.01, *p < 0.05. HR, hazard ratio; 
CI, confidence interval. 
 
 
Figure 6. Cox regression hazard ratios of combined cancer incidence and sleep timing midpoint 
tertiles, stratified by sex, body mass index, presence of at least one medical 
condition/comorbidity or presence of depression, for 19,822 participants in Alberta’s Tomorrow 
Project.  
Note: Intermediate sleep timing midpoint (Ref) = 3 h 47 min–4 h 8 min, early sleep timing midpoint < 3 h 47 min, 
late sleep timing midpoint > 4 h 8 min. The model was adjusted for age, sex (if not stratified variable), total 
household income, employment status, marital status, education, ethnicity, smoking status, body mass index (if not 
stratified variable), presence of at least one medical conditions/comorbidity (if not stratified variable), presence of 
depression (if not stratified variable), family history of cancer, sleep duration. **p < 0.01, *p < 0.05. HR, hazard 
ratio; CI, confidence interval. 
 
We also examined participant characteristics according to sex and case status for 19,822 
participants (7,518 males and 12,304 females) included in the sleep timing midpoint analysis 
(Table 2). Of these, a total of 1,322 participants (585 males and 737 females) developed cancer 
during the study follow-up period. The mean follow-up times for cancer and noncancer cases 
were 4.48 ± 4.46 and 8.70 ± 0.22 years, respectively, yielding a total of 166,875 person-years of 
follow-up. A larger proportion of cancer cases were classified as having a late sleep timing 
midpoint compared with noncancer cases. Similar to the participants included in the sleep 
duration analysis, a larger proportion of cancer cases were older, had a higher BMI, were less 
educated, had a lower total household income, were unemployed, were daily smokers, had at 
least one medical condition/comorbidity, had a family history of cancer and had >3 full-term 
pregnancies (females only) compared with noncancer cases. 
 
We investigated the strength of associations between sleep timing midpoint tertiles with 
combined and site-specific cancer incidence and found that a late sleep timing midpoint was 
associated with an increased risk of combined cancer incidence in the multivariate-adjusted 
model (Figure 5). Although no longer statistically significant (p = 0.07), a positive association 
remained between late sleep timing midpoint and combined cancer incidence in the latency 
multivariate-adjusted model. For breast cancer, a late sleep timing midpoint was associated with 
an increased risk of cancer in the multivariate- and latency multivariate-adjusted models. 
 
The sleep timing midpoint × medical condition interaction term was associated with combined 
cancer incidence when added to the multivariate-adjusted model (p = 0.01). However, sleep 
timing midpoint × sex (p = 0.33), sleep timing midpoint × BMI (p = 0.69) and sleep timing 
midpoint × depression (p = 0.16) interaction terms were not associated with combined cancer 
incidence in the multivariate-adjusted model. When testing for effect modification, a late sleep 
timing midpoint was associated with an increased risk of combined cancer incidence in females, 
but not males, as well as participants with a BMI ≥25 kg/m2 versus those with a BMI <25 
kg/m2 (Figure 6). Similarly, a late sleep timing midpoint was associated with an increased risk of 
combined cancer incidence in participants who reported at least one medical 
condition/comorbidity, but not in participants who reported an absence of medical 
conditions/comorbidities, as well as participants who reported having depression versus those 




This prospective cohort of approximately 45,000 Albertans is the largest to date in Canada to 
examine the associations between sleep duration and cancer incidence. We observed a U-shaped 
association between continuous sleep duration and cancer risk. However, the increased HRs for 
short and long sleep durations, compared with recommended sleep duration, were not 
statistically significant in the multivariate- and latency multivariate-adjusted models. These 
results may be partially explained by the small number of self-reported short and long duration 
sleepers in this cohort (≈25% and 5% of the cohort reported <7 or >9 h of sleep/night, 
respectively), thus limiting the power to detect associations with cancer risk. 
 
Our findings did show evidence of effect modification by certain covariates, which may 
undermine some of the abovementioned sleep duration category-cancer incidence associations. 
The associations for short and long sleep durations were stronger in females compared with 
males, with a statistically significant association between short sleep duration and combined 
cancer incidence in females. Specifically, short sleep duration was associated with combined 
cancer incidence in postmenopausal, but not premenopausal, females. Indeed, recent data from 
the National Health Interview Survey (Centers for Disease Control and Prevention) reported that 
women were more likely to report trouble falling asleep and staying asleep, and were more likely 
to wake up feeling less rested compared with men [67]. A second publication from the same 
group also reported that postmenopausal women were more likely to sleep <7 h/night, had a 
higher frequency of difficulty falling and staying asleep, and were less likely to wake up feeling 
well rested compared with premenopausal women [68]. Some [28, 32], but not all [18, 25, 35], 
studies have also reported an inverse association between sleep duration and breast cancer 
incidence in postmenopausal, but not premenopausal, females. It has been hypothesized that the 
occurrence of short sleep duration in postmenopausal women may result from the development 
of possible sleep disturbances and other symptoms (e.g. changes in sex-steroid hormone levels, 
weight gain, reduced insulin sensitivity) associated with the menopausal transition, which may 
increase the risk of developing certain types of cancers [69, 70]. 
 
We also noted an increased risk of cancer in short sleepers who reported daily alcohol intake, 
which was not present in participants who reported weekly, monthly, or no alcohol intake. 
Greater total alcohol intake in short duration sleepers compared with recommended and long 
duration sleepers was previously reported [62]. Although the causal nature of these associations 
cannot be determined in this study (i.e. whether daily alcohol intake leads to short sleep duration 
or being awake for longer leads to more opportunities for alcohol intake), these findings do 
suggest an interaction between alcohol intake and sleep duration which should be further 
explored in subsequent studies. Lastly, a statistically significant increase in cancer risk was noted 
in both short and long duration sleepers who reported at least one medical condition/comorbidity, 
as well as short duration sleepers who reported living with depression. Both short and long sleep 
durations have been consistently associated with a number of adverse health outcomes, such as 
obesity [2–6] and type 2 diabetes [7–9]. Sleep disturbances and short sleep durations are also a 
common side effect of depression [65, 71, 72]. It may be hypothesized that cancer risk is 
amplified by short or long sleep durations in individuals with at least one medical 
condition/comorbidity, including depression. Considering that many of the adverse health 
outcomes associated with both short and long sleep durations are also risk factors for a number 
of cancers, these findings could be especially valuable for the design of lifestyle interventions for 
cancer prevention that target sleep duration in individuals living with comorbidities or 
depression. 
 
For site-specific cancer risk, long sleep duration was associated with an increased risk of non-
Hodgkin lymphoma and hematological cancers in the fully adjusted models. Only one other 
cohort study assessed the associations between sleep duration and hematological cancers, 
reporting statistical trends for increased risks of non-Hodgkin lymphoma and myeloma in male 
short duration sleepers and a suggestive increased risk of non-Hodgkin lymphoma in female long 
duration sleepers [29]. Considering that long sleep duration can often be confounded by the 
presence of comorbidities/chronic health conditions and/or poorer sleep quality 
[15, 26, 49, 50, 73], it is possible that self-reported long sleep duration (or time spent in bed) 
may be associated with alterations in the immune-inflammation balance [74], thus increasing 
hematological cancer risk. Subsequent studies are needed to confirm these findings and 
investigate biomarker changes over time associated with short and long sleep duration for 
hematological cancer prevention. 
 
Although only available in a subset of the ATP cohort, this study is the first to assess the strength 
of associations between sleep timing midpoint with combined and site-specific cancer incidence. 
We observed an increased risk of combined and breast cancer incidence in participants classified 
as having a late sleep timing midpoint versus an intermediate sleep timing midpoint in the fully 
adjusted model which included sleep duration as a covariate. Effect modifications were also 
noted for sex, BMI, and the presence of medical conditions/comorbidities and depression, 
indicating that participants classified as having a late sleep timing midpoint who were females, 
had a BMI ≥25 kg/m2, reported having at least one medical condition/comorbidity and reported 
living with depression were at an increased risk for cancer. A late sleep timing midpoint has been 
recently associated with a greater BMI and food consumption in the evening [51], as well as an 
increased risk of insulin resistance [53] and gestational diabetes [52]. An increased risk of breast 
[54, 55] or prostate [40, 56, 57] cancers has also been observed in individuals with evening or 
mixed (i.e. neither morning nor evening) chronotypes compared with a morning chronotype. It 
has been hypothesized that evening chronotypes may be more susceptible to circadian 
disruptions and polymorphisms of certain circadian genes (e.g. Per3 gene) which may lead to 
tumor development and increase cancer risk [56, 75]. An in-laboratory protocol where 10 
females ate and slept according to a “28-hour day,” thus inducing circadian misalignment, led to 
systematic increases in postprandial glucose and insulin levels, coupled with decreases in leptin 
and sleep efficiency [76]. Variations in cortisol levels were also inverted (e.g. cortisol levels 
were highest at the beginning of the sleep period when they should be lowest), which may 
contribute to the observed changes in glycemia responses and leptin levels [76]. Taken together, 
it is possible that a late sleep timing midpoint, or a misalignment between sleep time and 
endogenous circadian rhythms, may lead to alterations in metabolic and hormonal profiles. If 
sustained, these alterations may lead to the development of cardiometabolic conditions (e.g. 
insulin resistance, obesity), which are also risk factors for a number of cancer sites, including 
breast [77]. 
 
This article has some strengths. Information on a large number of covariates were available in 
this cohort, and sensitivity analyses were performed by excluding cases diagnosed within 2 years 
of questionnaire completion. However, there is a risk of residual confounding since information 
on other covariates shown to be associated with sleep (e.g. current shift work, sleep medication 
use, habitual physical activity participation) [55–57, 67, 78, 79] were not consistently measured 
in this cohort. Similarly, menopausal status was not measured with Survey 2008, which 
contained the only data on sleep timing. Other limitations include the measurement of self-
reported sleep duration, bed- and wake-times with questionnaires. Specifically, studies have 
reported on average moderate-high correlations (0.3–0.75) between self-reported and objectively 
measured sleep duration, indicating a difference of ≈15–60 min/night in total sleep time between 
self-reported and objective measurements [80–85]. Lockley et al. [80] reported high correlations 
between subjective and objective measurements of sleep onset (0.77) and offset (0.88), however, 
lower correlations (≈0.10–0.40) were reported for sleep-wake state transitions (e.g. sleep onset 
latency, wake after sleep onset) in this study and others [82, 84]. Self-reported errors for sleep 
parameters may also be more prominent in certain populations (e.g. individuals with self-
reported poor sleep quality or a sleep efficiency <85%, high perceived psychological distress, 
younger age) [83, 85]. Therefore, the use of self-reported sleep measurements may lead to 
exposure misclassification. However, as previously reported [29], there is no evidence of 
differences in the occurrence of these reporting errors by cancer status, meaning that any 
exposure misclassification may bias our results toward the null. The small number of cases for 
certain cancer sites within the short and long sleep duration categories may have reduced the 
statistical power to detect an association. There is a risk of health literacy bias since only those 
participants who were able to comprehend, complete, and return the study questionnaires were 
included in this study. 
 
These findings suggest that sleep duration and sleep timing may play a role in cancer etiology. 
Furthermore, effect modification results suggest that other biological and behavioral components 
may directly impact the association between sleep duration and sleep timing with cancer 
incidence, and should be considered in future reports within this research area. Additional studies 
including objective assessments of sleep are needed to corroborate these findings and inform 
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